Exercise of Warrants

ReNeuron Group plc
15 November 2006



                              Exercise of Warrants



Guildford, UK, 15 November 2006: ReNeuron Group plc (LSE: RENE) gives notice
reminding Warrant holders that, in accordance with the terms of the Warrant
Instrument dated 4 August 2005 (as amended), the exercise period of the Warrants
shall end on 12 December 2006.



To the extent not previously validly exercised, the subscription rights
conferred pursuant to the terms of the Warrants will cease to be exercisable by
Warrant holders on 13 December 2006.



If and to the extent any Warrants remain unexercised ('Unexercised Warrants') as
at 13 December 2006 the Company may, in its discretion, appoint a trustee to
exercise such Warrants and sell Ordinary Shares thereupon issued provided that
the proceeds of sale, after deduction of costs and expenses incurred by the
trustee, will exceed the subscription price. Any such proceeds of sale in excess
of the exercise price and the costs and expenses of the trustee will thereafter
be distributed to those persons who held Unexercised Warrants on a pro-rata
basis.



The Company seeks to de-list the Warrants from trading on the AIM market of the
London Stock Exchange with effect from 13 December 2006.



There are currently 19,000,000 Warrants in issue. Each Warrant entitles the
holder to subscribe for one new Ordinary Share in the Company at a price of 10p
per share. There are currently 99,604,700 Ordinary Shares in issue.



The Directors hold a total of 88,080 Warrants and have confirmed their intention
to exercise the Warrants held by them in full.



The Company has today sent to each Warrant holder a letter detailing the manner
in which the Warrant subscription rights may be exercised. Further queries
concerning the exercise of such Warrant subscription rights should be made to
the Company Secretary on [phone]. Please note that neither the
Company Secretary nor any other representative of the Company can provide
investment or tax advice.





Enquiries:


ReNeuron
Michael Hunt, CEO                                       Tel: [phone]
John Sinden, CSO


Financial Dynamics
David Yates                                             Tel: [phone]
Nicola Daley



Notes to Editors



ReNeuron is a leading, UK-based adult stem cell therapy business.  The Group is
applying its novel stem cell platform technologies in the development of
ground-breaking stem cell therapies to serve significant and unmet or poorly-met
clinical needs.



ReNeuron has used its c-mycERTAM technology to generate genetically stable
neural stem cell lines.  This technology platform has multi-national patent
protection and is fully regulated by means of a chemically-induced safety
switch.  Cell growth can therefore be completely arrested prior to in vivo
implantation.



The Group's lead stem cell therapy, ReN001 for chronic stroke disability, is in
late pre-clinical development.  The Company plans to file for approval to
commence a Phase I clinical study in stroke by the end of 2006, with the study
commencing as soon as possible thereafter.   There are an estimated 50 million1
stroke survivors worldwide, approximately half of which are left with permanent
disabilities.  The healthcare costs of caring for these patients is estimated to
amount to $45 billion2 in the US alone.



The Group has also generated pre-clinical efficacy data with its ReN005 stem
cell therapy for Huntington's disease, a genetic and fatal neurodegenerative
disorder that affects around 1 in 10,000 people.  This programme is in
pre-clinical development.



In addition to its stroke and Huntington's disease programmes, ReNeuron is
developing stem cell therapies for Parkinson's disease, Type 1 diabetes and
diseases of the retina.



ReNeuron has also leveraged its stem cell technologies into non-therapeutic
areas - its ReNcell range of cell lines for use in research and in drug
discovery applications in the pharmaceutical industry.



ReNeuron's shares are traded on the London AIM market under the symbol RENE.L,
and its warrants are traded under the symbol RENW.L.



Further information on ReNeuron and its products can be found at
www.reneuron.com.



 1. MOSES (Morbidity and mortality after stroke - Eprosartan vs nitrendipine for
    secondary prevention) study, Feb 2006
 2. American Heart Association, Reporting Standards for Carotid Artery
    Angioplasty and Stent Placement, (Stroke, 2004; 35:e112).



This announcement contains forward-looking statements with respect to the
financial condition, results of operations and business achievements/performance
of ReNeuron and certain of the plans and objectives of management of ReNeuron
with respect thereto. These statements may generally, but not always, be
identified by the use of words such as 'should', 'expects', 'estimates',
'believes' or similar expressions. This announcement also contains
forward-looking statements attributed to certain third parties relating to their
estimates regarding the growth of markets and demand for products. By their
nature, forward-looking statements involve risk and uncertainty because they
reflect ReNeuron's current expectations and assumptions as to future events and
circumstances that may not prove accurate.  A number of factors could cause
ReNeuron's actual financial condition, results of operations and business
achievements/performance to differ materially from the estimates made or implied
in such forward-looking statements and, accordingly, reliance should not be
placed on such statements.




                      This information is provided by RNS
            The company news service from the London Stock Exchange